Britain and America have finalized a major bilateral deal that will guarantee zero duties on UK drug shipments entering the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to increase expenditure on drugs through the National Health Service (NHS). This pledge ensures that import taxes on these vital products will stay at nothing for a duration of the next three years.
This agreement follows previous statements to dramatically increase import taxes on branded pharmaceutical products, with increases discussed up to 100%.
"This arrangement between the United Kingdom reinforces the international landscape for new treatments and introduces long-overdue fairness to U.S.–U.K. drug exports," an announcement noted.
Trade Significance
Medicines are one of the the United Kingdom's biggest exports to the America, which is easily the primary market for leading British pharmaceutical firms.
Trade data show that in the year leading up to last September, the UK exported drugs totaling £11.1bn to the US. This value represented nearly one-fifth of British export trade in that span.
"This agreement safeguards work, boosts investment and paves the way for the UK to become a international leader for biotech and pharma," the Business and Trade Secretary remarked.
Specific UK Commitments
The deal involves several key changes from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new medicines to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a target to double overall public funding on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The sum drug companies must pay back to the NHS to prevent overspending will be restricted at fifteen percent. Previously, rebates topped twenty percent.
Broader Context
The deal takes place against a protracted tension between the pharmaceutical industry and the British authorities over spending levels and regulatory access.
The disagreement were heightened by assertions that American consumers were paying a premium for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or abandoned, while multi-billion-dollar investments have been pledged toward projects in the United States.
The Science Minister stated that the NHS had to increase expenditure on drugs, noting that its expenditure on drugs had shrunk as a share of its total funding over the past decade.
